KNP 2002
Alternative Names: KNP-2002; KV-0132Latest Information Update: 26 Jun 2023
At a glance
- Originator Kino Pharma
- Developer IWAKI SEIYAKU; Kino Pharma
- Class Antivirals; Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Warts
Most Recent Events
- 12 Jun 2023 Phase-II clinical trials in Warts in Japan (Topical) (NCT05896215)
- 06 Jun 2023 KinoPharma plans a phase II trial for Warts(In adults, In adolescents) in June 2023 (Topical, Ointment)(NCT05896215)
- 07 Apr 2023 KinoPharma files a notification of clinical trial (CTN) to PMDA in Japan for Warts